Evaluation of Speech Rhythm Training in Dyslexic Readers Aged 7 to 9 Years
NCT ID: NCT05996497
Last Updated: 2025-03-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
160 participants
INTERVENTIONAL
2023-10-05
2026-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Rhythmic Reading Training: Comparing the Rhythmic and Visual Contributions to Reading Improvement
NCT04995991
Role of Auditory Cortical Oscillations in Speech Processing and Dyslexia
NCT04277351
Telerehabilitation vs. in Presence Rehabilitation of Reading Disorders Using the Rhythmic Reading Training (RRT)
NCT04995471
Prediction and Intervention in Developmental Dyslexia
NCT02217696
Investigating Speech Sequencing in Neurotypical Speakers and Persons With Disordered Speech
NCT05437159
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study begins with a recruitment and inclusion period after diagnosis of dyslexia. During this study, 4 assessments are performed and include behavioral measures in the care setting and electrophysiological measures in the research setting:
* at time T1 before any remediation,
* at T2 after the first training,
* at T3 at most 7 days after the 2nd training session,
* at T4 seven weeks after T3.
After the T1 assessment, participants were randomized into 4 different groups (training 1 then training 2):
Group 1 : Auditory Rhythmic at 30 Hz then GraphoGame Group 2 : GraphoGame then Rhythmic Auditory at 30 Hz Group 3 : Auditory Rhythmic at low frequencies then GraphoGame Group 4 : GraphoGame then Auditory Low Frequency Rhythmic The first training period (total duration 6 weeks) according to the assigned group begins and takes place at the speech therapist's office and at home.
After the T2 evaluation, the 2nd training period (total duration 6 weeks) according to the assigned group begins and takes place at the SLP's office as well as at home.
The post-training evaluations T3 and T4 take place, respectively, 1 week and 7 weeks after the last training.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Auditory Rhythmic at 30 Hz then GraphoGame
Training 1 with Auditory Rhythmic at 30 Hz (6 weeks) then Training 2 with GraphoGame (6 weeks)
behavioral measures
behavioral measures
Electrophysiological measures
Electrophysiological measures
Training 1
Training 1
Training 2
Training 2
GraphoGame then Rhythmic Auditory at 30 Hz
Training 1 with GraphoGame (6 weeks) then Training 2 with Auditory Rhythmic at 30 Hz (6 weeks)
behavioral measures
behavioral measures
Electrophysiological measures
Electrophysiological measures
Training 1
Training 1
Training 2
Training 2
Auditory Rhythmic at low frequencies then GraphoGame
Training 1 with Auditory Rhythmic at low frequencies (6 weeks) then Training 2 with GraphoGame (6 weeks)
behavioral measures
behavioral measures
Electrophysiological measures
Electrophysiological measures
Training 1
Training 1
Training 2
Training 2
GraphoGame then Auditory Low Frequency Rhythmic
Training 1 with GraphoGame (6 weeks) then Training 2 with Auditory Rhythmic at Low Frequency Rhythmic (6 weeks)
behavioral measures
behavioral measures
Electrophysiological measures
Electrophysiological measures
Training 1
Training 1
Training 2
Training 2
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
behavioral measures
behavioral measures
Electrophysiological measures
Electrophysiological measures
Training 1
Training 1
Training 2
Training 2
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* in regular schooling
* have a diagnosis of dyslexia
* have a non-verbal intelligence assessment within the norm. Inclusion assessments must show a major reading disability without associated cognitive deficits.
* be equipped with a PC at home
* have given their assent and whose parents/legal guardians have given their oral consent
Exclusion Criteria
* have a neurological disorder (visual, auditory, executive)
* have an associated psychiatric disorder
* have a developmental delay.
7 Years
9 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut de l'Audition
OTHER
Institut Pasteur
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Diane Lazard, MD
Role: PRINCIPAL_INVESTIGATOR
Institut Pasteur
Anne-Lise Giraud, PhD
Role: STUDY_DIRECTOR
Institut Pasteur
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institut de l'Audition
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Diane Lazard, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-A01132-41
Identifier Type: OTHER
Identifier Source: secondary_id
2022-063
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.